Scott Sandell Buys 207,100 Shares of Korro Bio (NASDAQ:KRRO) Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Scott Sandell purchased 207,100 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were bought at an average cost of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the purchase, the insider directly owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. The trade was a 18.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Korro Bio Price Performance

Shares of Korro Bio stock opened at $12.80 on Friday. The firm has a 50 day simple moving average of $10.99 and a 200 day simple moving average of $20.18. Korro Bio, Inc. has a fifty-two week low of $5.20 and a fifty-two week high of $55.89. The firm has a market cap of $120.58 million, a P/E ratio of -1.03 and a beta of 2.98.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($5.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.93) by ($3.39). The firm had revenue of $1.29 million for the quarter, compared to analyst estimates of $0.43 million. Korro Bio had a negative return on equity of 99.63% and a negative net margin of 1,834.48%. On average, sell-side analysts expect that Korro Bio, Inc. will post -9.52 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald upped their price target on Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Friday. Raymond James Financial upgraded Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price objective for the company in a research report on Friday. Clear Str raised Korro Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 18th. Chardan Capital upgraded shares of Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $44.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its stake in shares of Korro Bio by 6,185.5% during the third quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock worth $9,542,000 after purchasing an additional 196,079 shares during the period. Emerald Mutual Fund Advisers Trust bought a new stake in Korro Bio in the third quarter valued at about $2,821,000. PNC Financial Services Group Inc. acquired a new position in Korro Bio in the third quarter valued at about $140,000. Wealth Forward LLC bought a new position in Korro Bio during the third quarter worth about $240,000. Finally, CWM LLC boosted its holdings in Korro Bio by 391.4% during the third quarter. CWM LLC now owns 2,693 shares of the company’s stock worth $129,000 after buying an additional 2,145 shares during the last quarter. Institutional investors and hedge funds own 13.18% of the company’s stock.

Key Headlines Impacting Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target, providing a prominent analyst endorsement that can attract momentum and institutional buyers. Read More.
• Positive Sentiment: Multiple major shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed large purchases (~207,100 shares at ~$11.11 each), signaling strong insider/large‑holder conviction and providing buying support. Read More.
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for hyperammonemia, is advancing a GalNAc oligo candidate for AAT deficiency (on track to nominate in Q2 2026), and closed an oversubscribed $85M private placement, which management says extends cash runway into H2 2028 — materially reducing near‑term financing risk. Read More.
• Neutral Sentiment: Revenue for Q4 modestly exceeded expectations ($1.29M vs. ~ $0.42M est.), but the amount is very small relative to R&D and operating burn, so near‑term profit improvement is limited. Read More.
• Negative Sentiment: Quarterly and annual results show heavy write‑downs and operating losses: Q4 EPS was a ($5.32) miss vs. consensus (~($1.93)), and full‑year net loss widened (reported ~$117.3M) driven by non‑cash impairment charges — highlighting high execution risk and potential for volatility if clinical progress stalls. Read More. Read More.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.